美波利祖马布
医学
不良事件报告系统
苯拉唑马布
不利影响
药物警戒
上市后监督
内科学
哮喘
嗜酸性粒细胞
作者
Shu-Peng Zou,Hai-Yun Yang,Mengling Ouyang,Qian Cheng,Xuan Shi,Minghui Sun
标识
DOI:10.1080/14740338.2023.2251382
摘要
Anti-IL-5 monoclonal antibodies (mAbs) targeting IL-5 or IL-5 R α (including mepolizumab, benralizumab, and reslizumab) are widely used for inflammatory diseases such as asthma, eosinophilia, and polyangiitis. However, real-world data regarding its safety in a large sample population are incomplete. So, we evaluated the safety of anti-IL-5 mAbs by pharmacovigilance analyzes based on related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS).
科研通智能强力驱动
Strongly Powered by AbleSci AI